Sjogren's Syndrome and Inflammation: When the Immune System Attacks Moisture Glands

Sjogren's syndrome is one of the more common autoimmune diseases, and like most autoimmune conditions it disproportionately affects women, typically emerging in midlife. Many people know it only for its most visible features: persistent dry eyes that feel gritty and dry mouth that makes speaking and swallowing difficult. Yet these symptoms are the surface expression of a much deeper immunological process in which the body's own defenses mistake healthy tissue for a threat and mount a sustained inflammatory response against it.

At its core, Sjogren's is a disease of misdirected inflammation. Immune cells that should be patrolling for pathogens instead accumulate in the glands that produce tears and saliva, gradually damaging them. Understanding this process helps explain why Sjogren's is not simply a nuisance of dryness but a systemic condition capable of affecting the whole body, and why it belongs to the same broad family of autoimmune inflammatory disorders as lupus and rheumatoid arthritis.

Lymphocytic Infiltration: The Inflammatory Attack on Exocrine Glands

The glands under siege. The defining feature of Sjogren's syndrome is lymphocytic infiltration of the exocrine glands, the moisture-producing glands that include the lacrimal glands of the eyes and the salivary glands of the mouth. In a healthy gland, secretory cells produce tears or saliva in an orderly way. In Sjogren's, clusters of immune cells, predominantly T and B lymphocytes, invade the gland tissue and form dense inflammatory foci around the ducts. A minor salivary gland biopsy showing these focal lymphocytic aggregates is one of the classic diagnostic findings.

How inflammation shuts down secretion. As lymphocytes accumulate, they release inflammatory cytokines that disrupt the normal function of the glandular cells and interfere with the nerve signals that trigger secretion. The result is a progressive decline in tear and saliva production. This is why the dryness of Sjogren's tends to be persistent and worsening rather than intermittent: the inflammatory infiltrate does not resolve on its own, and over time it can replace functional gland tissue with scarring and fibrosis.

Sicca symptoms and their consequences. The combination of dry eyes and dry mouth is referred to collectively as sicca symptoms. Beyond discomfort, the loss of protective tears and saliva has real consequences: chronic dry eye can damage the surface of the cornea, and reduced saliva accelerates dental decay, promotes oral infections, and impairs taste and swallowing. Many patients also experience dryness of other mucosal surfaces, reflecting how broadly the inflammatory process affects moisture-producing tissue throughout the body.

Autoantibodies and the Type I Interferon Signature

Anti-Ro/SSA and anti-La/SSB. A hallmark of Sjogren's syndrome is the presence of specific autoantibodies, most notably anti-Ro/SSA and anti-La/SSB. These antibodies target proteins involved in the normal processing of cellular RNA. Their presence in the blood is both a diagnostic clue and a window into the disease mechanism, because the immune complexes they form help perpetuate the inflammatory cycle. Not every patient carries these antibodies, but when present they are strongly associated with the autoimmune inflammation that defines the disease.

The interferon connection. One of the most important discoveries in Sjogren's research is the prominent type I interferon signature seen in many patients. Type I interferons are signaling proteins normally deployed to fight viral infections. In Sjogren's, these same molecules are chronically overexpressed, creating a self-sustaining loop: immune complexes containing anti-Ro and anti-La stimulate immune cells to produce more interferon, which in turn activates additional immune pathways and drives further inflammation in the glands. This interferon-driven state helps explain why the disease behaves as if the body is perpetually fighting an infection that is not there.

B cell overactivity. Sjogren's is also marked by hyperactivity of B lymphocytes, the immune cells that produce antibodies. This overactivity contributes to the production of autoantibodies and elevated immunoglobulin levels, and it underlies one of the more serious long-term concerns in Sjogren's: an increased risk of lymphoma arising from the chronically stimulated B cell population. This link between sustained inflammation and cancer risk underscores why Sjogren's is best understood as a systemic immunological disease rather than a localized dryness problem.

Beyond the Glands: Systemic Inflammation and Biomarkers

A whole-body disease. While the glands bear the most visible burden, the inflammation of Sjogren's frequently extends to other organs. Many patients experience joint pain and swelling, profound fatigue, and Raynaud's phenomenon. More significant systemic involvement can affect the peripheral nerves, causing neuropathy, as well as the lungs, kidneys, and blood vessels. This systemic reach reflects the fact that the underlying immune dysregulation is not confined to the tear and salivary glands but circulates throughout the body.

Inflammatory markers in Sjogren's. Laboratory testing in Sjogren's often reveals signs of ongoing inflammation and immune activation. The erythrocyte sedimentation rate is commonly elevated, frequently driven by the high immunoglobulin levels characteristic of the disease. C-reactive protein, or CRP, may be normal or only mildly raised in uncomplicated Sjogren's, but it can rise during flares or when systemic complications develop. Because CRP and ESR can diverge in autoimmune conditions, comparing the two provides useful context, a distinction explored in our overview of CRP versus ESR.

Fatigue as an inflammatory symptom. One of the most disabling features of Sjogren's is a deep, persistent fatigue that many patients rank as more limiting than the dryness itself. This fatigue is thought to stem in part from the same inflammatory cytokines and interferon activity that drive the glandular disease. Cytokines acting on the brain can produce the sense of exhaustion, cognitive fog, and malaise often described as sickness behavior, connecting the physical inflammation of Sjogren's to its impact on energy and quality of life.

Managing Sjogren's Through an Anti-Inflammatory Lens

Medical management of the immune process. Because Sjogren's is driven by autoimmune inflammation, treatment often aims to calm the overactive immune response while relieving symptoms. Beyond artificial tears and saliva substitutes that address dryness directly, physicians may use immune-modulating medications for patients with significant systemic involvement. Emerging therapies specifically target the B cell overactivity and interferon pathways at the heart of the disease. Any medication decisions should always be made in partnership with a rheumatologist familiar with the individual case.

Diet and lifestyle support. While no diet cures Sjogren's, an anti-inflammatory dietary pattern rich in omega-3 fatty acids, vegetables, and whole foods and low in ultra-processed items may help reduce the overall inflammatory burden and support general well-being. Staying well hydrated, using humidifiers, and avoiding caffeine and alcohol that worsen dryness are practical measures that improve daily comfort. Some patients find that omega-3 supplementation offers modest relief of dry eye symptoms.

Stress, sleep, and inflammation. Chronic stress and poor sleep amplify inflammatory signaling and can worsen autoimmune symptom flares. Because the fatigue and inflammation of Sjogren's are self-reinforcing, prioritizing restorative sleep and incorporating stress-reduction practices such as gentle exercise, mindfulness, and pacing can meaningfully influence symptom severity. These approaches do not replace medical care, but they address the lifestyle factors that modulate the inflammatory state.

Monitoring the bigger picture. Because Sjogren's carries a risk of systemic complications and its inflammatory activity can wax and wane, ongoing monitoring is central to good management. Regular follow-up allows a care team to catch organ involvement early, watch for the rare but serious lymphoma risk, and adjust treatment as the disease evolves. Tracking inflammatory markers over time, alongside symptoms, helps build a clearer picture of how the disease is behaving and how well interventions are working.